Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NAD bounces Notox to FTC

This article was originally published in The Tan Sheet

Executive Summary

Claims for A.D. Pharma's alcohol-intoxication reducer have been referred to the Federal Trade Commission after the firm failed to make a "bona fide good faith attempt to bring its advertising into compliance with NAD's recommendations," the Council of Better Business Bureaus division says in an Aug. 19 release. Notox was the subject of a NAD inquiry in the spring (1"The Tan Sheet" May 3, 2004, In Brief). At issue were claims that clinical studies indicate the Panax ginseng/citrus reticulate supplement "combats the effects of alcohol intoxication." The watchdog group notes that the television commercial NAD objected to has been permanently discontinued...

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts